GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
Phase 1
Not yet recruiting
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK3862995BDrug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT06979518
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT06979323
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Phase 3
Not yet recruiting
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 960
- Registration Number
- NCT06961214
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Phase 3
Not yet recruiting
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 981
- Registration Number
- NCT06959095
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Phase 3
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT06956170
- Locations
- 🇯🇵
GSK Investigational Site, Hokkaido, Japan
🇯🇵GSK Investigation Site, Fukushima City, Fukushima-Ken, Japan
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
- First Posted Date
- 2025-04-14
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT06926673
- Locations
- 🇺🇸
GSK Investigational SIte, Nashville, Tennessee, United States
🇪🇸GSK Investigational Site, Malaga, Spain
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT06897527
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Tumours, Gynecological
- Interventions
- Drug: Anticancer therapy 1Drug: Anticancer therapy 2Drug: Anticancer therapy 3Drug: Anticancer therapy 4
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 360
- Registration Number
- NCT06796907
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 67
- Registration Number
- NCT06887933
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT06885034
© Copyright 2025. All Rights Reserved by MedPath